Neoadjuvant Toripalimab and Axitinib Shows Activity in Mucosal Melanoma
Source: Cancer Therapy Advisor, November 2023
Neoadjuvant treatment with toripalimab and axitinib has demonstrated efficacy in a phase 2 trial of patients with resectable mucosal melanoma, according to researchers.
“Our study suggests that toripalimab plus axitinib may provide a promising new neoadjuvant treatment approach for patients with resectable mucosal melanoma,” the researchers wrote in Annals of Oncology.
This single-arm trial (ClinicalTrials.gov Identifier: NCT04180995) enrolled 29 patients with resectable mucosal melanoma. Their median age was 62 (range, 34-72) years, and 72.4% were women.